<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="752">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04438850</url>
  </required_header>
  <id_info>
    <org_study_id>cover_1</org_study_id>
    <nct_id>NCT04438850</nct_id>
  </id_info>
  <brief_title>COVidIVERmectin: Ivermectin for Treatment of Covid-19</brief_title>
  <acronym>COVER</acronym>
  <official_title>Randomized, Double-blind, Multi Centre Phase II, Proof of Concept, Dose Finding Clinical Trial on Ivermectin for the Early Treatment of COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IRCCS Sacro Cuore Don Calabria di Negrar</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Istituto Di Ricerche Farmacologiche Mario Negri</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>IRCCS Sacro Cuore Don Calabria di Negrar</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, multi-centre, randomized, double-blind trial to assess efficacy and safety of
      ivermectin for the treatment of initial infection with SARS-CoV2 infection.

      Study arms: A) placebo B) ivermectin 600 μg/kg daily for 5 consecutive days (I_600) +
      placebo. C) ivermectin 1200 μg/kg daily at empty stomach with water for 5 consecutive days
      (I_1200). Patients will be randomized at emergency room of hospitals as well as at outpatient
      ambulatory care as well as at home, according to routine procedures of recruiting centres.

      In arm A and B, the number of placebo tablets to be administered will be calculated by the
      study dedicated pharmacist considering the number of tablets that should be taken in case a
      patient with the same weight is assigned to arm C.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary objectives

      The study is aimed:

        1. at defining if ivermectin, administered at dosage of 600 μg/kg or 1200 μg/kg QD for five
           consecutive days is safe in patients with initial, asymptomatic or oligosymptomatic
           SARS_CoV-2 infection,

        2. at defining if ivermectin, administered at the dosage(s) found to be safe decreases the
           viral load of SARS-CoV-2 at Day 7.

      Secondary objectives To assess

        1. the temporal profile of viral load at baseline, day 7, 14 and 30

        2. the time to clinical cure (for symptomatic patients)

        3. the proportion of patients with virological clearance at day 14 and 30.

        4. the hospitalization rate.

        5. the COVID-19 Severity Score at day 14 and 30

      STUDY DESIGN

      This is a multicentre, prospective, randomized, double-blind, adaptive phase II dose finding
      study.

      Patients meeting the inclusion criteria will be asked to participate to the study and
      randomized in a 1:1:1 ratio to either:

        -  Placebo arm (arm A): placebo will be identical in appearance to ivermectin in order to
           preserve blinding and will be administered p.o. at empty stomach with water once daily,
           for 5 days

        -  Intervention arms: a) Ivermectin, single dose 600 μg/kg, for 5 days (I_600) and placebo
           (arm B) ; b) Ivermectin, single dose 1200 μg/kg, for 5 days (I_1200) (arm C) ); these
           drugs will be administered p.o. once daily, for 5 days.

      In arm A and B, the number of placebo tablets to be administered will be calculated by the
      study dedicated pharmacist considering the number of tablets that should be taken in case a
      patient with the same weight is assigned to arm C.

      Patients will be randomized by a centralized computer system. At randomization a treatment ID
      is assigned to the patient. Once a treatment ID is assigned this must not be re-assigned even
      in cases of errors.

      Enrolled subjects will be identified by a unique subject number (patient code) that will
      remain consistent for the duration of the study.

      Patients will be recruited at the emergency room of hospitals, and/or among asymptomatic
      hospital workers found positive for SARS-CoV-2 at routine screening and/or in outpatient
      ambulatory settings, and/or at home, if not meeting the clinical criteria for
      hospitalization, according to the routine procedure of each participating site. The expected
      duration of subject inclusion in the study is of 1 month, or until the planned number of
      subjects to be enrolled will be reached.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 31, 2020</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Ivermectin and placebo treatment will be double blinded, i.e. the treatment will be unknown to both the subject and the treating physician. The hospital pharmacist will be unblinded to study treatment because in charge to prepare the study treatment according to randomization arm.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>SADR</measure>
    <time_frame>14 days</time_frame>
    <description>Number of serious adverse drug reaction</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Viral load</measure>
    <time_frame>Assessed at day 7</time_frame>
    <description>Quantitative viral load as measured by quantitative, digital droplet PCR.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Trend viral load</measure>
    <time_frame>Days 7 and 14 from baseline</time_frame>
    <description>1. Trend over time of quantitative viral load at Day 7 and 14 as measured by quantitative, digital droplet PCR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical resolution</measure>
    <time_frame>Assessed on Day 30</time_frame>
    <description>Time to clinical resolution (for symptomatic patients).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral clearance</measure>
    <time_frame>assessed on days 14 and 30</time_frame>
    <description>Time from diagnosis to documented viral clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virological clearance</measure>
    <time_frame>Assessed at day 14 and 30</time_frame>
    <description>Proportion of patients with virological clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hospitalization rate</measure>
    <time_frame>Day 30</time_frame>
    <description>rate of hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity score</measure>
    <time_frame>Assessed at Day 14 and Day 30</time_frame>
    <description>COVID-19 Severity Score (Coronavirus Diseases 19 Severity Score) - min value 1 (&quot;no limitation of activities), max value 8 (&quot;death&quot;). Higher scores mean worse outcome</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">102</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>I_600</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ivermectin 600 μg/kg daily for 5 consecutive days (I_600) + placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>I_1200</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ivermectin 1200 μg/kg daily at empty stomach with water for 5 consecutive days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ivermectin</intervention_name>
    <description>Patients will be administered a single oral daily dose of approximately 600 μg/Kg (486-679 μg/Kg as rounded to a whole number of tablets), or 1200 μg/Kg (1098-1286 μg/Kg).</description>
    <arm_group_label>I_1200</arm_group_label>
    <arm_group_label>I_600</arm_group_label>
    <other_name>Ivermectin 9 mg cp by Chemo group</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients should take placebo orally on an empty stomach with water</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo supplied by chemo group</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;=18 years

          -  Positivity at RT-PCR per SARS_CoV2 (nasopharyngeal swabs)

          -  Consent to participation to the study and to the processing of personal data

          -  COVID-19 Severity Score &lt; 3

          -  Patient able to take oral drugs

        Exclusion Criteria:

          -  Pregnant or lactating women (pregnancy test not required, if doubt patient is
             excluded)

          -  Subjects suffering from known CNS diseases

          -  Lack of (or inability to provide) informed consent

          -  Patient under dialysis

          -  Any severe medical condition with a prognosis of &lt; 6 months

          -  Patients under warfarin treatment

          -  Patients under antiviral treatment

          -  Patients under chloroquine phosphate or hydroxychloroquine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zeno Bisoffi</last_name>
    <role>Principal Investigator</role>
    <affiliation>IRCCS Sacro Cuore Don Calabria hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zeno Bisoffi, PhD</last_name>
    <phone>+390456013326</phone>
    <email>zeno.bisoffi@sacrocuore.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>IRCCS Sacro Cuore Don Calabria hospital</name>
      <address>
        <city>Negrar</city>
        <state>Verona</state>
        <zip>37024</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dora Buonfrate</last_name>
      <email>dora.buonfrate@sacrocuore.it</email>
    </contact>
    <investigator>
      <last_name>Zeno Bisoffi</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dora Buonfrate</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico S. Orsola</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Luciano Attard</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Luigi Sacco</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Spinello Antinori</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale di Rovereto</name>
      <address>
        <city>Rovereto</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giovanni Pedrotti</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Amedeo di Savoia</name>
      <address>
        <city>Turin</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guido Celleri</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic/ISGlobal</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>José Muñoz</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital La Paz-Carlos III</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elena Trigo Esteban</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>April 10, 2020</study_first_submitted>
  <study_first_submitted_qc>June 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 19, 2020</study_first_posted>
  <last_update_submitted>August 11, 2020</last_update_submitted>
  <last_update_submitted_qc>August 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ivermectin</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ivermectin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The anonymized database will be uploaded into a public repository</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>The database will be available upon publication of the results</ipd_time_frame>
    <ipd_access_criteria>The data will be available in a public repository</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

